PDF(Pubmed)
Abstract：
UNASSIGNED: This study investigated a safe and effective bolus dose and lockout time for patient-controlled sedation (PCS) with dexmedetomidine for dental treatments. The depth of sedation, vital signs, and patient satisfaction were investigated to demonstrate safety.
UNASSIGNED: Thirty patients requiring dental scaling were enrolled and randomly divided into three groups based on bolus doses and lockout times: group 1 (low dose group, bolus dose 0.05 µg/kg, 1-minute lockout time), group 2 (middle dose group, 0.1 µg/kg, 1-minute), and group 3 (high dose group, 0.2 µg/kg, 3-minute) (n = 10 each). ECG, pulse, oxygen saturation, blood pressure, end-tidal CO2, respiratory rate, and bispectral index scores (BIS) were measured and recorded. The study was conducted in two stages: the first involved sedation without dental treatment and the second included sedation with dental scaling. Patients were instructed to press the drug demand button every 10 s, and the process of falling asleep and waking up was repeated 1-5 times. In the second stage, during dental scaling, patients were instructed to press the drug demand button. Loss of responsiveness (LOR) was defined as failure to respond to auditory stimuli six times, determining sleep onset. Patient and dentist satisfaction were assessed before and after experimentation.
UNASSIGNED: Thirty patients (22 males) participated in the study. Scaling was performed in 29 patients after excluding one who experienced dizziness during the first stage. The average number of drug administrations until first LOR was significantly lower in group 3 (2.8 times) than groups 1 and 2 (8.0 and 6.5 times, respectively). The time taken to reach the LOR showed no difference between groups. During the second stage, the average time required to reach the LOR during scaling was 583.4 seconds. The effect site concentrations (Ce) was significantly lower in group 1 than groups 2 and 3. In the participant survey on PCS, 8/10 in group 3 reported partial memory loss, whereas 17/20 in groups 1 and 2 recalled the procedure fully or partially.
UNASSIGNED: PCS with dexmedetomidine can provide a rapid onset of sedation, safe vital sign management, and minimal side effects, thus facilitating smooth dental sedation.
UNASSIGNED: Thirty patients requiring dental scaling were enrolled and randomly divided into three groups based on bolus doses and lockout times: group 1 (low dose group, bolus dose 0.05 µg/kg, 1-minute lockout time), group 2 (middle dose group, 0.1 µg/kg, 1-minute), and group 3 (high dose group, 0.2 µg/kg, 3-minute) (n = 10 each). ECG, pulse, oxygen saturation, blood pressure, end-tidal CO2, respiratory rate, and bispectral index scores (BIS) were measured and recorded. The study was conducted in two stages: the first involved sedation without dental treatment and the second included sedation with dental scaling. Patients were instructed to press the drug demand button every 10 s, and the process of falling asleep and waking up was repeated 1-5 times. In the second stage, during dental scaling, patients were instructed to press the drug demand button. Loss of responsiveness (LOR) was defined as failure to respond to auditory stimuli six times, determining sleep onset. Patient and dentist satisfaction were assessed before and after experimentation.
UNASSIGNED: Thirty patients (22 males) participated in the study. Scaling was performed in 29 patients after excluding one who experienced dizziness during the first stage. The average number of drug administrations until first LOR was significantly lower in group 3 (2.8 times) than groups 1 and 2 (8.0 and 6.5 times, respectively). The time taken to reach the LOR showed no difference between groups. During the second stage, the average time required to reach the LOR during scaling was 583.4 seconds. The effect site concentrations (Ce) was significantly lower in group 1 than groups 2 and 3. In the participant survey on PCS, 8/10 in group 3 reported partial memory loss, whereas 17/20 in groups 1 and 2 recalled the procedure fully or partially.
UNASSIGNED: PCS with dexmedetomidine can provide a rapid onset of sedation, safe vital sign management, and minimal side effects, thus facilitating smooth dental sedation.
摘要：
■这项研究调查了使用右美托咪定进行牙科治疗的患者控制镇静（PCS）的安全有效的推注剂量和锁定时间。镇静的深度，生命体征,并对患者满意度进行调查以证明安全性.
■招募了30名需要牙科洁牙的患者，并根据推注剂量和锁定时间随机分为三组：第1组（低剂量组，推注剂量0.05µg/kg，1分钟锁定时间),第2组（中剂量组，0.1微克/千克，1分钟),和第3组(高剂量组，0.2微克/千克，3分钟）（每个n=10）。心电图,脉搏,氧饱和度,血压,呼气末二氧化碳，呼吸频率，测量并记录脑电双频指数（BIS）评分。该研究分两个阶段进行：第一个阶段涉及无需牙科治疗的镇静作用，第二个阶段包括使用牙齿洁齿的镇静作用。患者被指示每10秒按一次药物需求按钮，入睡和醒来的过程重复1-5次。在第二阶段,在牙齿缩放期间，患者被指示按下药物需求按钮.反应性丧失（LOR）定义为对听觉刺激6次无反应，确定睡眠发作。在实验前后评估患者和牙医的满意度。
■30名患者（22名男性）参加了这项研究。在排除第一阶段出现头晕的患者后，对29例患者进行了缩放。第3组直到第一次LOR的平均给药次数（2.8次）明显低于第1组和第2组（8.0和6.5次，分别)。达到LOR所需的时间在组间没有差异。在第二阶段,在缩放期间达到LOR所需的平均时间为583.4秒。第1组的效应位点浓度(Ce)显著低于第2组和第3组。在PCS的参与者调查中，第3组有8/10报告部分记忆丧失，而第1组和第2组的17/20全部或部分回忆了该过程。
■使用右美托咪定的PCS可以提供快速的镇静作用，安全的生命体征管理，和最小的副作用，从而促进牙齿顺利镇静。
■招募了30名需要牙科洁牙的患者，并根据推注剂量和锁定时间随机分为三组：第1组（低剂量组，推注剂量0.05µg/kg，1分钟锁定时间),第2组（中剂量组，0.1微克/千克，1分钟),和第3组(高剂量组，0.2微克/千克，3分钟）（每个n=10）。心电图,脉搏,氧饱和度,血压,呼气末二氧化碳，呼吸频率，测量并记录脑电双频指数（BIS）评分。该研究分两个阶段进行：第一个阶段涉及无需牙科治疗的镇静作用，第二个阶段包括使用牙齿洁齿的镇静作用。患者被指示每10秒按一次药物需求按钮，入睡和醒来的过程重复1-5次。在第二阶段,在牙齿缩放期间，患者被指示按下药物需求按钮.反应性丧失（LOR）定义为对听觉刺激6次无反应，确定睡眠发作。在实验前后评估患者和牙医的满意度。
■30名患者（22名男性）参加了这项研究。在排除第一阶段出现头晕的患者后，对29例患者进行了缩放。第3组直到第一次LOR的平均给药次数（2.8次）明显低于第1组和第2组（8.0和6.5次，分别)。达到LOR所需的时间在组间没有差异。在第二阶段,在缩放期间达到LOR所需的平均时间为583.4秒。第1组的效应位点浓度(Ce)显著低于第2组和第3组。在PCS的参与者调查中，第3组有8/10报告部分记忆丧失，而第1组和第2组的17/20全部或部分回忆了该过程。
■使用右美托咪定的PCS可以提供快速的镇静作用，安全的生命体征管理，和最小的副作用，从而促进牙齿顺利镇静。
